923590-78-7Relevant articles and documents
THERAPEUTIC COMPOUNDS
-
Paragraph 0137; 0138, (2018/07/06)
no abstract published
ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG
-
, (2015/06/03)
The present invention relates to aryl linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhbiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.
Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor
McCauley, John A.,McIntyre, Charles J.,Rudd, Michael T.,Nguyen, Kevin T.,Romano, Joseph J.,Butcher, John W.,Gilbert, Kevin F.,Bush, Kimberly J.,Holloway, M. Katharine,Swestock, John,Wan, Bang-Lin,Carroll, Steven S.,Dimuzio, Julian M.,Graham, Donald J.,Ludmerer, Steven W.,Mao, Shi-Shan,Stahlhut, Mark W.,Fandozzi, Christine M.,Trainor, Nicole,Olsen, David B.,Vacca, Joseph P.,Liverton, Nigel J.
experimental part, p. 2443 - 2463 (2010/09/03)
A new class of HCV NS3/4a protease inhibitors which contain a P2 to P4 macrocyclic constraint was designed using a molecular-modeling derived strategy. Exploration of the P2 heterocyclic region, the P2 to P4 linker, and the P1 side chain of this class of